InMed Pharmaceuticals director holds 27,868 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
InMed Pharmaceuticals Inc. director Michelle Patricia Pernice reported direct holdings of 27,868 common shares following the merger effective November 6, 2026. The shares were received in exchange for her Pre-Merger Mentari common shares. Of the reported shares, 19,740 remain subject to forfeiture restrictions and vest in equal monthly installments through August 13, 2029, subject to continued service on each vesting date.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Common Stock F1, F2 | -- | -- | -- |
Footnotes (2)
- F1. Effective as of November 6, 2026 (the "Effective Time"), (i) Indigo Merger Sub Corp., a wholly owned subsidiary of Mentari Therapeutics, Inc. (formerly known as InMed Pharmaceuticals Inc.), a Nevada corporation (the "Issuer"), merged with and into Mentari Therapeutics, Inc., a Delaware corporation ("Pre-Merger Mentari"), with Pre-Merger Mentari continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Mentari merged with and into Indigo Merger Sub II, LLC, a second wholly owned subsidiary of the Issuer ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Mentari Therapeutics Operating Company LLC (the "Second Merger" and, together with the First Merger, the "Merger").
- F2. Represents shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for the shares of Pre-Merger Mentari's common stock held by the Reporting Person prior to the Merger. Each share of Pre-Merger Mentari's restricted common stock held at the Effective Time was exchanged for 0.20065 restricted shares of the Issuer's common stock. Of these shares of common stock, 19,740 remain subject to forfeiture restrictions and vest in equal monthly installments through August 13, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Key Terms
restricted common stock technical
forfeiture restrictions technical
wholly owned subsidiary technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.